**No Evidence of Compensatory Changes in Energy Balance, Despite Reductions in Body Weight and Liver Fat, During Dapagliflozin Treatment in Type 2 Diabetes Mellitus: A Randomised, Double-blind, Placebo-controlled, Cross-over Trial (ENERGIZE)**

**Surya Panicker Rajeev1,2\*, Carl A Roberts3\*, Emily Brown1,2, Victoria S Sprung2,4, Jo A Harrold3, Jason CG Halford5, Andrej Stancak3, Emma J Boyland3, Graham J Kemp6, Julie Perry7, Elaine Howarth7, Richard Jackson7, Andrew Wiemken8, Richard Schwabb8, Daniel J Cuthbertson1,2 & John PH Wilding1,2.**

1Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK

2Liverpool University Hospitals NHS Foundation Trust, University Hospital Aintree, Liverpool, UK

3Department of Psychology, Institute of Population Health, University of Liverpool, Liverpool, UK

4Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK

5School of Psychology, University of Leeds, Leeds UK

6Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK

7Liverpool Clinical Trials Centre (LCTC), University of Liverpool, Liverpool, UK

8Division of Sleep Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

\*These 2 authors contributed equally to the manuscript and are sharing lead authorship

**Corresponding author:** Dr Carl Alexander Roberts, Department of Psychology, University of Liverpool. [Carl.roberts@liverpool.ac.uk](mailto:Carl.roberts@liverpool.ac.uk)

**Conflicts of interest:** JW has acted as a consultant, received institutional grants, and given lectures on behalf of pharmaceutical companies developing or marketing medicines used for the treatment of diabetes and obesity, specifically Alnylam, AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Lilly, Napp, Novo Nordisk, Pfizer, Rhythm Pharma, Saniona, Shionogi, Sanofi, Takeda and Ysopia. DJC has competing interests with AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Lilly & Novo Nordisk and has received educational support from Perspectum. JCGH has acted as a consultant for Boehringer Ingelheim and Novo Nordisk. CAR has acted as a consultant for Boehringer Ingelheim. Dr. Schwab reports grant and/or research support from ResMed, Inspire, and CryOSA, royalties from UpToDate and Merck Manual, research consulting for Eli Lilly, and is on the Medical Advisory Board for eXciteOSA. Other authors have no competing interests.

**Acknowledgements:** This study was funded by a grant from Bristol Myers Squibb. The authors acknowledge the help of Valerie Adams, Senior Radiographer at the Liverpool Magnetic Resonance and Imaging Centre (LIMRIC), University of Liverpool.

**Abstract**

**Aims** This study assessed the impact of dapagliflozin on food intake, eating behaviour, energy expenditure, MRI-determined brain response to food cues and body composition in patients with type 2 diabetes mellitus (T2D).

**Materials and methods** Patients were given dapagliflozin 10mg once daily in a randomised, double-blind, placebo-controlled trial with short-term (1 week) and long-term (12 weeks) crossover periods. The *primary outcome* was the difference in *test meal* *food intake* between long-term dapagliflozin and placebo treatment. Secondary outcomes included short-term differences in *test meal food intake*, short-and long-term differences in *appetite and* *eating rate*, *energy expenditure*, and *fMRI brain activity in relation to food images*. We determined differencesin glycated haemoglobin, weight, liver fat (by 1H MRS) and subcutaneous/visceral adipose tissue (SAT/VAT) volumes (by MRI).

**Results** 52 patients (43% female) were randomised; with analysis of 49 patients: median age 58 years, weight 99.1 kg, BMI 35 kg/m2, HbA1c 49 mmol/mol. Dapagliflozin reduced HbA1c by 9.7 mmol/mol (95% CI 3.91 to 16.27, *p* = 0.004), and body weight (-2.84 *vs*. -0.87 kg) *vs.* placebo. There was no short- or long-term difference in test meal food intake between dapagliflozin and placebo [mean difference 5.7g (95% CI -127.9 to 139.3, *p* = 0.933); 15.8g (95% CI -147.7 to 116.1, *p* = 0.813), respectively] nor in the rate of eating, energy expenditure, appetite, or brain responses to food cues. Liver fat (median reduction -4.7 vs. 1.95%), but not SAT/VAT, decreased significantly with 12 weeks of dapagliflozin.

**Conclusions** The reduction in body weight and liver fat with dapagliflozin was not associated with compensatory adaptations in food intake or energy expenditure.

**Introduction**

SGLT2 inhibitors (SGLT2i) have become an established pharmacological treatment for type 2 diabetes (T2D) (1-4) with glucose- and weight-lowering effects (2, 3, 5-7), conferring cardiovascular and reno-protective benefits (8-15). As such their use has been extended to other clinical populations, such as those with chronic kidney disease and/or heart failure, with/without T2D.

SGLT2 inhibition results in a typical daily net urinary glucose excretion of ~75 grams with a daily energy loss of ~300 kcal (1200 kJ/day) (16, 17). Thus, the predicted weight loss after 24 weeks of treatment with the SGLT2i dapagliflozin (assuming no compensatory changes in food intake, energy expenditure and no diuresis), based on the calculated energy loss, would be ~7kg. However, clinical data so far suggest that the observed total weight loss with dapagliflozin 10mg dose is substantially less [~2.5–3.2 kg (18-20)]. These data suggest that there are compensatory mechanisms that attenuate weight loss with chronic treatment (21), e.g. an increase in food intake and/or a reduction in energy expenditure. Preclinical studies provide evidence for compensatory mechanisms, for example, in SGLT2 knockout mice energy expenditure is higher and respiratory quotient (RQ) lower, consistent with a shift from carbohydrate to fat metabolism with compensatory increases in feeding and drinking (22). Human studies also demonstrate a shift from carbohydrate to fat metabolism (23).

Studies examining the effect of SGLT2i on appetite and energy expenditure in humans are sparse. In the recent randomised, double blind, placebo-controlled SEESAW study, the effects of empagliflozin 25mg once daily for 24 weeks were compared with those of placebo, placebo plus dietary restriction (to match the energy deficit elicited by SGLT2i), and with a combination of empagliflozin and dietary restriction. Despite significant changes in weight (placebo, 0.44 kg; placebo plus diet, 1.91 kg; empagliflozin, 2.22 kg; and empagliflozin plus diet, 5.74 kg), there were no between group differences in the primary outcome measure, change in postprandial circulating total peptide-YY (PYY) during a 3-hour mixed-meal tolerance test, from baseline to 24 weeks. Similarly, there were no differences in postprandial total glucagon-like peptide-1 (GLP-1), acylated ghrelin, subjective appetite perceptions or other key components of energy balance (24). It is important to understand these physiological mechanisms that underpin this attenuation of weight loss with SGLT2i therapy to maximise the weight loss achievable with this class of drugs in people with T2D, but the results of this study point against a role of changes in postprandial appetite-regulatory gut peptides.

The ENERGIZE trial was designed to directly test the hypothesis that 12 weeks of treatment with the SGLT2i, dapagliflozin 10 mg daily, in individuals with T2D would cause a compensatory increase in food intake, compared with placebo, that would attenuate the anticipated weight loss. Short-term (1 week) and long-term (12 weeks) changes in food intake and appetite (within meal and across the day) using test meals and visual analogue scales (VAS) were assessed. Energy expenditure using indirect calorimetry, brain reactivity to images of hedonic foods with functional MRI (fMRI) and abdominal MRI-determined changes in body composition (subcutaneous and visceral adipose tissue volume and liver fat) to assess adaptive responses to glycosuria-induced negative energy balance were also assessed as secondary outcome measures.

**Material and methods**

*Trial design and study participants* This was an outpatient, double-blind, placebo-controlled crossover study. Fifty-two participants with T2D were recruited: aged 18–75 years, with glycated haemoglobin (HbA1c) ≥6.5% (48 mmol/mol) or ≥7.0% (53 mmol/mol) in patients treated without or with sulfonylureas, respectively, but < 11% (97mmol/mol). After routine screening tests, each participant visited the study centre on 12 occasions. All participants received 7 days of either dapagliflozin or placebo for short-term assessments, followed by 12 weeks of each treatment for long-term assessments. Each participant served as their own control with the cross-over between drug and placebo at the short-term and long-term assessment points. The 7-day cross-over measurements were designed to assess short-term effects of treatment on compensatory mechanisms (at a time-point where significant weight loss would not have yet occurred), while the long-term cross-over were designed to investigate compensatory mechanisms during the dynamic weight loss phase (Figure 1).

The full trial protocol has already been published (25).

*Study design* As shown in the schematic (Figure 1), the study consisted of four time periods. All participants received dapagliflozin and placebo for the short and long-term studies, over 7-10 days, with a cross over period of 12-weeks. Forty-five participants completed the study protocol, 49 were analysed as per the pre-specified modified intention to treat analysis that included all participants who took at least one dose of study drug (Figure 2).

**Biochemistry and haematology:** Blood samples were taken for liver function, lipid profile, thyroid function, HbA1c and haematology (full blood count), at baseline to ensure screening criteria were met, and at the end of each long-term treatment period.

**Test meals and appetite assessments:** On each of the test meal and appetite assessment days participants attended the lab at 8 a.m and confirmed that they had had nothing to eat or drink other than water from midnight the previous evening. At 9 a.m participants were served a fixed load breakfast (as per Halford et al., 2010) for full nutrition information and standard operating procedure see supplementary materials. Participants were asked to rate their degrees of hunger, fullness, satisfaction, desire to eat, perception of how much they could eat (prospective consumption) and nausea on a 100mm VAS scale pre and post breakfast and at 10 a.m., 11 a.m., 12 noon, 3 p.m., 4 p.m. and 5 p.m.

At 1 p.m participants were given a test-meal consisting of pasta with a tomato based sauce (for full nutritional information and standard operating procedure see supplementary materials). Participants were told to eat ad-libitum until they were comfortably full and to signal to the experimenter when they had finished. Food intake and within meal assessment of appetite (hunger, fullness, desire to eat and prospective consumption) were collected using VAS and the Sussex Ingestion Pattern Monitor (SIPM V.2.0.13, University of Sussex). Rate of eating was calculated in grams per second, and satiety quotient was calculated was calculated by dividing the difference of pre and post meal hunger by the total weight of food consumed.

**Indirect calorimetry:** Energy expenditure and Respiratory Exchange Ratio (RER) were assessed by indirect calorimetry using a ventilated hood system (GEM Nutrition Limited, Daresbury Innovation Centre, UK). Measurements were started after the participant had been under the hood for 5 min to allow for acclimatisation, and data were collected over a 20 min period. Indirect calorimetry was performed pre and post breakfast and at 10 a.m., 11 a.m., 12 noon, 3 p.m., 4 p.m. and 5 p.m.

**MR methods:** After screening for MRI contraindications, participants and underwent MR scanning at the Liverpool Magnetic Resonance and Imaging Centre (LIMRIC), part of Liverpool Shared Research Facilities, in the University of Liverpool Faculty of Health and Life Sciences. Brain fMRI used a 3.0 T Trio scanner (Siemens Healthineers, Erlangen, Germany), and body composition and liver fat measurements used a 1.5 T Symphony scanner (Siemens Healthineers, Erlangen, Germany)

**Functional MRI**: fMRI data was acquired at 7 days and 12 weeks of dapagliflozin/placebo treatment. Participants fasted from 22:00 the previous night and undertook a fasted scan at 09:00 hours in which Blood Oxygen Level Dependent (BOLD) responses were recorded to passively viewing sets of images of high calorie (hedonic) foods *vs* non-food control objects (high calorie foods > control – first level contrast) in the fasted state, then again 1 hour after consuming a fixed load breakfast. Results were analysed using the following comparisons (second level analysis):

1. Dapagliflozin > placebo, at scan 1 (pre-breakfast/fasted) after 7 days treatment;

2. Dapagliflozin > placebo at scan 2 (post-breakfast) after 7 days treatment;

3. Dapagliflozin > placebo at scan 1 (pre-breakfast) after 12 weeks treatment;

4. Dapagliflozin > placebo at scan 2 (post-breakfast) after 12 weeks treatment.

In each case the significance level was set at *p* < 0.05, whole-brain corrected for family-wise error rate (FWE). Minimum cluster size threshold was not specified. Analysis was limited to 17 participants who completed all necessary scans for analysis of short-term treatment (dapagliflozin v placebo at 1 week), and 17 participants who completed all necessary scans for analysis of long-term treatment (dapagliflozin v placebo at 12 weeks). For further details of fMRI methods and analysis see Supplementary Materials.

**Assessment of body composition**: Body composition and liver fat was assessed at baseline, and at 14 and 26 weeks.Liver fat (intrahepatocellular triglyceride) was measured by magnetic resonance spectroscopy (1H MRS). Body fat volume, compromising abdominal subcutaneous adipose tissue (SAT) and abdominal visceral adipose tissue (VAT), was measured by MRI. For details of MRI and 1H MRS methods see Supplementary Materials.

**Statistical analysis**

*Sample size calculation* The primary outcome measure was energy intake after 12-weeks. Based on previous research (26), and using PROC POWER in SAS V.9.3, we estimated that 52 participants were required to detect a 12.5% change in food intake by paired *t*-test with 80% power at a two-sided 5% level of significance (based on a correlation between measurements of 0.7 and a between-participant SD of 165g). The 12.5% change in food intake assumes a baseline test meal consumption of 460g, with a 12.5% change equating to a 57.5g increase in food intake. This calculation allows for 20% participant dropout.

*Body composition* For changes in body composition, only the differences in MRI determined abdominal subcutaneous adipose tissue (SAT) and abdominal visceral adipose tissue (VAT) and liver fat were measured between visit 4 (14 weeks) and visit 5 (26 weeks). Results of the two groups who received 12 weeks of placebo (Groups B/C) and 12 weeks of dapagliflozin (Groups A/D) were pooled. Comparison with the baseline scan visit 1 was not deemed appropriate as all four treatment groups had received 1 week of dapagliflozin in the acute study period.

**Results**

*Screening and randomisation:* Of 71 participants screened from August 2015 to August 2017, 52 were randomized to the study. The 49 participants who took at least one dose of study medication were included in the final analysis.

*Demographic characteristics:* The mean age of participants was 57.3 years (SD 9.4). 63% were males. All but one participant were of white ethnicity (Table 1).

*Details of diabetes treatment:* Of 49 participants (4 participants were on diet only, 44 were on metformin, 15 were on sulfonylurea: gliclazide and 4 were on DPP-4 inhibitors: 3 sitagliptin, 1 linagliptin). 14 were on a combination of metformin and gliclazide and 4 were on a combination of metformin and sitagliptin/linagliptin (Figure 3).

*Biochemical and anthropometric characteristics* The mean baseline weight of the study participants (n=49) was 107-Kg (SD 18.5), BMI was 35.2-kg/m2 (SD 5.6). Mean HbA1c was 60.4-mmol/mol (SD 11.2), mean eGFR was 82.3 (SD 9.1).

**Primary outcome measure: Food intake**

***Effects of dapagliflozin on food intake during standard test meal after 12 weeks treatment*** There was no difference in food intake between dapagliflozin and placebo treatment after 12 weeks (Figure 3). The mean food intake of participants in the test meal during dapagliflozin treatment was 433 g, compared to 428 g grams during placebo treatment (mean (SE) treatment difference 5.7 (67), 95% CI -128 to 139, *p =* 0.93).

**Secondary outcome measures**

**Clinical end points:** Dapagliflozin reduced HbA1c by 9.7-mmol/mol (95% CI 3.91 to 16.27, *p* = 0.004), and body weight (-2.84 *vs*. -0.87 kg) *vs.* placebo.

**Energy balance**

***Effects of dapagliflozin on food intake during standard test meal after 7 days treatment:*** There was no difference in food intake between dapagliflozin and placebo treatment after 7 days (Figure 3). The mean food intake in the test meal during dapagliflozin treatment was 423 g compared to 438 g during placebo treatment (mean (SE) treatment difference -16 (67), 95% CI =148 to 116, *p* = 0.81).

***Effect of dapagliflozin on within-meal measures of appetite at 7 days and 12 weeks:***

There was no difference in the rate of eating or satiety quotient between dapagliflozin and placebo treatment in the short term or long term (Table 3). There was no difference in within-meal hunger, fullness, prospective consumption or desire to eat scores between dapagliflozin and placebo at 7 days or 12 weeks.

***Effect of dapagliflozin on appetite fluctuation across the day at 7 days and 12 weeks***

There were no differences in hunger, fullness, prospective consumption, desire, thirst, satisfaction, or nausea across the day at 7 days or 12 weeks (see Table 2 for *p*-values and CIs).

***Effect of dapagliflozin on energy expenditure and RER at 7 days and 12 weeks***There were no differences in total energy expenditure between dapagliflozin and placebo treatment in the short-term period of 7 days (95% CI -22.22 to -41.63, *p* = 0.54), or the long-term period of 12 weeks, (95% CI -49.43 to 18.43, *p =* 0.37) (Figure 3).After 7 days treatment, dapagliflozin had a significantly lower mean RER compared to placebo (0.92 vs 0.97 respectively, 95% CI -0.10 to -0.02, *p* = 0.003). This difference was not seen at 12 weeks (95% CI -0.05 to 0.03, *p* = 0.47).

**Body composition**

***Effect of dapagliflozin on body composition and liver fat at 12 weeks***

*Liver fat:* There was a significant reduction in median liver fat between participants treated with dapagliflozin (-4.7% (-6.475, 0.25)) compared with placebo (1.95 (-0.15, 5.4)) between weeks 14 and 26; p=.033 (Table 4).

*SAT/VAT:* There was no significant reduction in median visceral adipose tissue or subcutaneous adipose tissue volumes fat between participants treated with dapagliflozin compared with placebo between weeks 14 and 26 (Table 4).

**Brain activity in response to food**

***Effect of dapagliflozin on dapagliflozin on neuropshysiological response to food cues at 7 days and 12 weeks (fMRI):***

There were no significant differences in brain activation between dapagliflozin and placebo treatment in any of the four contrasts specified in the Methods.

**Adverse Events:** There were five serious adverse events (SAE) during the study period with placebo/treatment: 2 non-ST elevation myocardial infarction, 1 atrial fibrillation, 1 abdominal pain of unknown cause, and 1 pleurisy. All included hospitalisation and 3 patients had their treatment withdrawn as a result. There were 63 adverse events reported throughout the trial, and the most common being polyuria, polydipsia, and urinary tract infections.

**Discussion**

The ENERGIZE trial is among the first human studies to examine the mechanisms underlying the discrepancy between the estimated and actual weight loss due to dapagliflozin treatment in a randomised, double-blind, placebo-controlled, crossover trial. The results demonstrate that dapagliflozin does not induce a compensatory increase in test meal food intake, nor accompanying increases in ratings of appetite across the day after short or long-term treatment, despite reductions in body weight and liver fat. Dapagliflozin also produced no short- or long-term effects on within-meal ratings of appetite, or eating rate, energy expenditure, or brain activation in relation to food images. Taken together our data suggest that changes in appetite, food intake, and energy expenditure are not the explanation for the discrepancy between the observed and anticipated weight loss during dapagliflozin treatment. It follows that other mechanisms must responsible.

Findings are consistent with those recently reported in the SEESAW study (27) which found no change in subjectively-reported measures of energy intake or appetite perceptions with empagliflozin treatment (alone or in combination with energy restricted diet) relative to placebo, in addition to no change in PYY or other appetite related hormones (ghrelin, GLP-1) (27). Hence, data from the only two available RCTs in humans both support the notion that SGLT2i treatment is not associated with a compensatory increase in energy intake, changes in appetite, or in central (ENERGIZE) or peripheral (SEESAW) drivers of eating behaviour.

In contrast, the results of both studies are discordant with those from mathematical modelling studies which have suggested compensatory increases in energy intake with SGLT2i. These studies, however, used a different retrospective study design to conduct hypothetical modelling based on a series of assumptions. Polidori *et al.* (2016) calculated that weight loss because of SGLT2i results in an increase in energy intake of around 100 kcal/day per kilogram of lost body weight, a three-fold increase compared to corresponding energy expenditure adaptations (28). Ferrannini *et al.* (2015) modelled responses in patients with T2D who received empagliflozin 25 mg/day over 90 weeks with measurements of body weight, estimated glomerular filtration rate and fasting plasma glucose (29). The model indicated a 13% increase in energy intake (269 kcal/day) with a 2% increase in daily energy expenditure due to diet-induced thermogenesis, which accounted for the 70% reduction in predicted body weight losses.

Indeed, if there was any compensatory increase in humans, there may be reasons why we could not demonstrate this in the current study. First, food intake was only measured during the test meal. It is possible that subjects behaved differently outside the research laboratory which we would not have been able to capture. To assess this, a different methodological design would have been required to capture the energy intake changes 24 hours of the day throughout the study duration. However, such studies are cumbersome, expensive, and would not have been practical in our setting. Second, it must be considered whether patients made a conscious effort (despite their instructions) to restrict their food intake during dapagliflozin treatment, somehow becoming aware of their treatment condition and knowing that dapagliflozin is associated with weight loss. However, given the lack of difference in subjectively reported hunger/appetite perceptions, or in brain responses to hedonic/palatable foods, it appears unlikely that there was conscious behavioural control suppressing increased appetite or hedonic attraction to foods. In addition, the observed changes in glycated haemoglobin (HbA1c), blood pressure and body weight, consistent with previous dapagliflozin studies, suggest that treatment compliance was not an explanation for null effects observed in the current study.

The only two secondary outcome measures which showed a difference were RER and liver fat. RER was significantly lower after 7 days of dapagliflozin treatment compared to placebo. This indicates that short-term dapagliflozin treatment induces a shift in substrate utilization from carbohydrate to lipid metabolism and is consistent with animal data (30) and other studies in humans (31). This difference in RER was not replicated in the long-term study period of 12 weeks. However, it is possible that after 12 weeks treatment, the participants were very close to reaching a new steady state (i.e. weight has reached a plateau), so reversion of RER towards baseline might be expected. Even the small amounts of weight loss seen in this study should result in decreased energy expenditure, so the observation that this did not change could suggest that the lower weight loss than expected was due to energy conservation rather than an increase in food intake. Further analysis using the mathematical models provided by Hall et al might help answer this question (21). Energy expenditure data from ENERGIZE is similar to the studies reported by Ferrannini *et al.* (2014) and Merovci et al. (2014) which provided insight into whole-body metabolic adaptation in SGLT2i treatment (31, 32).

The modest weight loss with dapagliflozin treatment was associated with a significant reduction in MRI-determined liver fat although not in abdominal visceral and subcutaneous adipose tissue (VAT and SAT) volumes. many previous studies and a recent meta-analysis confirm that SGLT2i can reduce liver fat, although there is much to learn, particularly on the impact of SGLT2 on liver fibrosis (33-36). However, their potential impact in patients with NAFLD, with or without T2D, is increasingly being recognised (37).

It will be interesting to observe the impact of the combination of SGLT2is and GLP-1 analogues on appetite responses, energy expenditure, and body composition, including liver fat/fibrosis in future mechanistic studies (38). Both classes of drug cause weight loss, albeit through different mechanisms. The knowledge from such mechanistic studies is necessary for treatment optimisation in personalised, patient centred approaches to weight management. In addition, the link between such medications and gut microbiota requires further exploration, as pharmaceuticals can impact microbiome composition which in turn can affect a range of physiological and metabolic outcomes. However, the only study in humans to date suggests that Dapagliflozin treatment does not significantly alater gut microbiome alpha diversity or composition (39).

In conclusion, and as expected, dapagliflozin induced an early (transient) shift to fat metabolism, and longer-duration (12 weeks) treatment reduced HbA1c, body weight and liver fat, but not subcutaneous or visceral adipose tissue volumes. Despite (albeit less than expected) weight loss, dapagliflozin was not associated with any short term or long-term compensatory increases in food intake or energy expenditure. Dapagliflozin did not influence the psychological drivers of eating behaviour such as the subjective experiences of appetite related phenomena, and brain reactivity to food cues.

**Dissemination**

This study was conducted in accordance with Good Clinical Practice (GCP), as defined by the International Conference on Harmonisation (ICH) and in compliance with the European Union Directive 2001/20/EC transposed into UK law as statutory instrument 2004 No 1031: Medicines for Human Use (Clinical Trials) Regulations 2004 and all subsequent amendments and the United States Code of Federal Regulations, Title 21, Part 50 (21CFR50). The study was approved by the NRES North-West—Liverpool Central Research Ethics Committee (14/NW/0340; protocol number UoL000987). The trial was registered with the MHRA and has been granted a Clinical Trial Authorisation (CTA). The CTA reference is its EudraCT Number: 2013-004264-60

**Table 1**Demographic characteristics, haematology/biochemistry, and body composition of the study participants

|  |  |  |
| --- | --- | --- |
| **Age, mean (SD)** |  | 57.3 (9.4) |
| **Gender, n (%)** |  |  |
| Female |  | 18 (37) |
| Male |  | 31 (63) |
| **Ethnicity, n (%)** |  |  |
| White |  | 48 (98) |
| African |  | 1 (2) |
| **Smoking status, n (%)** |  |  |
| Current Smoker |  | 4 (8) |
| Ex-Smoker |  | 20 (41) |
| Never Smoked |  | 25 (51) |
| **Alcohol status, n (%)** |  |  |
| None |  | 7 (14) |
| Regular |  | 29 (59) |
| **Haematology/Biochemistry** | ***n*** | **Mean (SD)** |
| ***Glycaemic parameters*** |  |  |
| HbA1c (mmol/mol) | 49 | 60.4 (11.2) |
| ***Renal/electrolytes*** |  |  |
| Sodium (mmol/l) | 46 | 140 (2) |
| Potassium (mmol/l) | 45 | 4.5 (0.4) |
| Urea (mmol/l) | 46 | 5 (1.2) |
| Creatinine (µmol/l) | 46 | 74 (14) |
| eGFR (ml/min/1.73m2) | 46 | 82 (9) |
| ***Liver*** |  |  |
| Bilirubin (µmol/L) | 46 | 9 (4.5) |
| Alanine Transaminase (IU/l) | 45 | 36 (20) |
| Alkaline Phosphatase (IU/l) | 46 | 77 (19) |
| Albumin (g/l) | 46 | 45 (7) |
| ***Other*** |  |  |
| Haemoglobin (g/l) | 46 | 141 (13) |
| **Body mass and composition** |  |  |
| Weight (kg) | 49 | 101.7 (18.5) |
| Body mass index (kg/m2) | 49 | 35.2 (5.6) |
| Subcutaneous adipose tissue (SAT) volume (l) | 27 | 7.5 (3.3) |
| Visceral adipose tissue (VAT) volume (l) | 27 | 5.1 (2.5) |
| Liver fat (%) | 32 | 19.9 (16) |

**Table 2** Mean appetite measures (out of 100 on Visual Analogue Scales) across the day at 7 days and 12 weeks

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | 7 days | | | | | | | | | | 12 weeks | | | | | | | |
|  | ***n*** | **Placebo**  **mean** | | ***n*** | | **Dapa**  **mean** | | ***p*** | | **95%**  **CI** | | ***n*** | **Placebo**  **mean** | ***n*** | **Dapa**  **mean** | ***p*** | **95%**  **CI** |
| Hunger | 47 | 29.67 | 48 | | 31.04 | | 0.30 | | (-1.54, 4.97) | | 45 | | 32.18 | 46 | 30.62 | 0.34 | (-4.99, 1.73) |
| Fullness | 47 | 56.22 | 48 | | 55.58 | | 0.59 | | (-4.55 2.59) | | 45 | | 56.98 | 46 | 56.54 | 0.72 | (-4.35, 3.01) |
| Prospective  consumption | 47 | 31.85 | 48 | | 31.69 | | 0.94 | | (-2.95, 3.17) | | 45 | | 33.34 | 46 | 32.63 | 0.64 | (-3.91, 2.40) |
| Desire | 47 | 31.93 | 48 | | 31.69 | | 0.90 | | (-3.13, 3.54) | | 45 | | 34.03 | 46 | 33.46 | 0.84 | (-3.80, 3.08) |
| Thirst | 47 | 32.17 | 48 | | 32.42 | | 0.95 | | (-2.91, 2.73) | | 45 | | 32.00 | 46 | 33.68 | 0.43 | (-1.76, 4.06) |
| Satisfaction | 47 | 62.69 | 48 | | 61.57 | | 0.46 | | (-4.44, 2.04) | | 45 | | 61.45 | 46 | 60.23 | 0.32 | (-5.03, 1.64) |
| Nausea | 47 | 5.44 | 48 | | 5.36 | | 0.99 | | (-4.08, 4.11) | | 45 | | 10.16 | 46 | 7.14 | 0.17 | (-7.20, 1.25) |


**Table 3** Within-meal appetite measures at 7 days and 12 weeks

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | 7 days | | | | | | 12 weeks | | | | | | |
|  | ***n*** | **Placebo**  **mean** | ***n*** | **Dapa**  **mean** | ***p*** | **95%**  **CI** | ***n*** | **Placebo**  **mean** | ***n*** | **Dapa**  **Mean** | ***p*** | **95%**  **CI** |
| Rate of eating (g/sec) | 43 | 0.91 | 43 | 0.82 | 0.51 | (-0.31, 0.16) | 41 | 0.91 | 43 | 0.90 | 0.97 | (-0.23, 0.24) |
| Satiety quotient | 47 | 0.13 | 46 | 0.12 | 0.98 | (-2.76, 2.70) | 43 | 0.70 | 43 | 2.14 | 0.36 | (-1.53, 4.15) |

**Table 4** Changes in liver fat and visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) with dapagliflozin and placebo [N = number scanned in substudy].

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **Placebo**  **(Groups B & C)** | **Dapagliflozin**  **(Groups A & D)** | ***p*** |
| **Liver fat (%)** | Visit 4, median (IQR) [N] | 5.85 (2.83, 16.75) [14] | 19.45 (8.73, 34.25) [14] |  |
|  | Visit 5, median (IQR) [N] | 14.4 (3.53, 18.35) [10] | 21.05 (7.3, 29.58) [12] |  |
|  | Visit 5 - Visit 4, median (IQR) [N] | 1.95 (-0.15, 5.4) [10] | -4.7 (-6.475, 0.25) [12] | **0.033** |
| **VAT** | Visit 4, median (IQR) [N] | 4.863 (2.91, 6.38) [14] | 4.235 (2.991, 7.16) [14] |  |
| Visit 5, median (IQR) [N] | 4.865 (2.66, 6.41) [12] | 4.218 (3.224, 6.306) [11] |  |
| Visit 5 - Visit 4, median (IQR) [N] | -0.073 (-0.36, 0.19) [12] | -0.032 (-0.307, 0.11) [11] | 0.611 |
| **SAT** | Visit 4, median (IQR) [N] | 6.36 (5.41, 8.65) [14] | 6.743 (5.234, 7.637) [14] |  |
| Visit 5, median (IQR) [N] | 5.932 (5.05, 8.31) [12] | 6.224 (4.528, 7.184) [11] |  |
| Visit 5 - Visit 4, median (IQR) [N] | -0.084 (-0.332, 0.005) [12] | -0.005 (-0.322, 0.159) [11] | 0.998 |

**Figure 1** Study protocol schematic

****

**Figure 2** CONSORT diagram explaining patient flow through the study

Graphical user interface, application, Word

Description automatically generated

**Figure 3** Long-term and short-term changes in energy intake (**A**) and energy expenditure (**B**) with dapagliflozin (hatched bars) versus placebo (black bars).

Chart, bar chart, waterfall chart

Description automatically generated

**B**

**A**

**References**

1. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocrine reviews. 2011;32(4):515-31.

2. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262-74.

3. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33-59.

4. Abdul-Ghani MA, DeFronzo RA. Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport. J Intern Med. 2014;276(4):352-63.

5. Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep. 2012;12(3):230-8.

6. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes, obesity & metabolism. 2014;16(5):457-66.

7. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients. J Am Heart Assoc. 2017;6(6).

8. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46.

9. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-306.

10. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24.

11. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28.

12. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57.

13. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008.

14. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-9.

15. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-57.

16. Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013;62(10):3324-8.

17. Rajeev SP, Cuthbertson DJ, Wilding JP. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes, obesity & metabolism. 2016;18(2):125-34.

18. Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord. 2013;13:58.

19. Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, et al. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(11):e0166125.

20. Cai X, Yang W, Gao X, Chen Y, Zhou L, Zhang S, et al. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. Obesity (Silver Spring). 2018;26(1):70-80.

21. Hall KD, Sacks G, Chandramohan D, Chow CC, Wang YC, Gortmaker SL, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet. 2011;378(9793):826-37.

22. Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60(3):890-8.

23. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients. 2016.

24. Sargeant JA, King JA, Yates T, Redman EL, Bodicoat DH, Chatterjee S, et al. The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial. Diabetes, obesity & metabolism. 2022;24(8):1509-21.

25. Rajeev SP, Sprung VS, Roberts C, Harrold JA, Halford JC, Stancak A, et al. Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol. BMJ open. 2017;7(1):e013539.

26. Halford J, Boyland E, Cooper S, Dovey T, Huda M, Dourish C, et al. The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. Journal of Psychopharmacology. 2010;24(1):99-109.

27. Davies M J SJ, Khunti K. The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes EASD annual meeting 20202020.

28. Polidori D, Sanghvi A, Seeley RJ, Hall KD. How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake. Obesity (Silver Spring). 2016;24(11):2289-95.

29. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38(9):1730-5.

30. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012;20(8):1645-52.

31. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499-508.

32. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509-14.

33. Johansson L, Hockings PD, Johnsson E, Dronamraju N, Maaske J, Garcia-Sanchez R, et al. Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. Diabetes, obesity & metabolism. 2020:10.1111/dom.14004.

34. Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, et al. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). Diabetes Care. 2018;41(8):1801-8.

35. Kahl S, Gancheva S, Strassburger K, Herder C, Machann J, Katsuyama H, et al. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Diabetes Care. 2020;43(2):298-305.

36. Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. The Lancet Gastroenterology & Hepatology.

37. Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L. SGLT2 inhibitors as the Most promising influencers on the outcome of non-alcoholic fatty liver disease. International Journal of Molecular Sciences. 2022;23(7):3668.

38. Brown E, Wilton MM, Sprung VS, Harrold JA, Halford JCG, Stancak A, et al. A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol BMJ open. 2021;11(7):e045663.

39. van Bommel E, Herrema H, Davids M, Kramer M, Nieuwdorp M, van Raalte D. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes. Diabetes & metabolism. 2020;46(2):164-8.